Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

NCT06755684 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

EGFR
Non-Small Cell Lung Cancer
Locally Advanced Non-Small Cell Lung Cancer
Pemetrexed
Carboplatin
Bevacizumab
Antineoplastic Agents
Tyrosine Kinase Inhibitor

Interventions

DRUG: Befotertinib combined Bevacizumab
DRUG: Befotertinib combined platinum-based double chemotherapy

Sponsor

Peng Zhang